



(11)

EP 2 796 875 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 2 (W2 B1)
Corrections, see
Bibliography INID code(s) 54

(51) Int Cl.:
G01N 33/574 ^(2006.01)

(48) Corrigendum issued on:
25.11.2020 Bulletin 2020/48

(45) Date of publication and mention
of the grant of the patent:
27.03.2019 Bulletin 2019/13

(21) Application number: **13164922.0**

(22) Date of filing: **23.04.2013**

(54) **Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis**

Hemmer von für das Sekretom eines Chondrozyts spezifischen Proteinen zur Behandlung von Brustkrebsmetastase

Inhibiteurs de protéines spécifiques de sécrétome d'un chondrocyte pour utilisation dans le traitement de la métastase du cancer du sein

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(43) Date of publication of application:
29.10.2014 Bulletin 2014/44

(73) Proprietor: **Albert-Ludwigs-Universität Freiburg
79098 Freiburg (DE)**

(72) Inventors:
• **Shastri, Prasad
79112 Freiburg (DE)**
• **Christensen, Jon
79117 Freiburg (DE)**

(74) Representative: **Krauss, Jan
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München (DE)**

(56) References cited:
**US-A1- 2008 206 766 US-A1- 2008 262 203
US-A1- 2011 105 724 US-A1- 2012 172 235
US-B1- 6 410 268 US-B1- 6 645 491**

- **JENNIFER L HALPERN ET AL: "Mesenchymal stem cells promote mammary cancer cell migration via the CXCR2 receptor", CANCER LETTERS, NEW YORK, NY, US, vol. 308, no. 1, 28 April 2011 (2011-04-28), pages 91-99, XP028378022, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2011.04.018 [retrieved on 2011-05-02]**
- **Y-L HSU ET AL: "Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/Snail signaling pathway", ONCOGENE, vol. 32, no. 37, 8 October 2012 (2012-10-08), pages 4436-4447, XP055080273, ISSN: 0950-9232, DOI: 10.1038/onc.2012.444**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 796 875 B8

- DE CEUNINCK F ET AL: "The inflammatory side of human chondrocytes unveiled by antibody microarrays", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 323, no. 3, 22 October 2004 (2004-10-22), pages 960-969, XP027194456, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2004.08.184 [retrieved on 2004-09-17]